DaVita Inc. is a leading provider of kidney dialysis services in the U.S., with a market cap of $7.3 billion. Analysts expect an adjusted EPS of $3.24 for Q4 2025, up 44.6% from the year-ago quarter. Fiscal 2025 predictions include an adjusted EPS of $10.70 and $12.89 for fiscal 2026. DaVita shares have decreased 36.1% over the past 52 weeks, underperforming the S&P 500 Index and State Street Health Care Select Sector SPDR ETF. After Q3 2025 results, shares tumbled 6.2% due to higher patient care costs, increased expenses, and lower dialysis volumes. Analysts’ consensus view on DVA stock is cautious with a “Hold” rating.

Read more at Barchart: Here’s What to Expect From DaVita’s Next Earnings Report